

Question: Should AspireAssist® vs. non-surgical management be used for weight loss?

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Aspire Assist	non-surgical management	Relative (95% CI)	Absolute (95% CI)		
%EWL (follow up: mean 1 years)												
1	randomised trials	not serious ^a	not serious	not serious	serious ^b	none	82	31	-	MD 21.7% more (13.75 more to 29.65 more)	⊕⊕⊕○ MODERATE	CRUCIAAL
IWQL (follow up: mean 1 years)												
1	randomised trials	not serious	not serious	not serious	serious ^c	none	82	31	-	MD 2.9 higher (1.66 lower to 7.46 higher)	⊕⊕⊕○ MODERATE	BELANGRIJK
Improvement in %HbA1c (follow up: mean 1 years)												
1	randomised trials	not serious	not serious	not serious	not serious	none	82	31	-	MD 0.14 more (0 to 0.28 more)	⊕⊕⊕⊕ HIGH	BELANGRIJK
Morbidity (follow up: mean 1 years)												
1	randomised trials	not serious	not serious	not serious	very serious ^d	none	5/82 (6.1%)	0/31 (0.0%)	OR 4.47 (0.24 to 83.27)	0 fewer per 1.000 (from 0 fewer to 0 fewer)	⊕⊕○○ LOW	CRUCIAAL

CI: Confidence interval; MD: Mean difference; OR: Odds ratio